Neuroinflammation in FTLD

Launched by LEIDEN UNIVERSITY MEDICAL CENTER · Mar 10, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "Neuroinflammation in FTLD," is focused on understanding the role of neuroinflammation in several types of frontotemporal lobar degeneration (FTLD), which includes conditions like Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP). Researchers want to learn how neuroinflammation affects the disease, identify specific markers that can distinguish between different types of FTLD, and find ways to predict how the disease might progress. Participants will undergo advanced MRI scans and provide blood and spinal fluid samples, along with undergoing various clinical evaluations to help gather important data.

To be eligible for this study, participants should be between 65 and 74 years old and be able to undergo an MRI. Those with certain diagnoses related to FTLD, such as PSP or specific genetic mutations, may qualify. However, individuals with other neurological or psychiatric disorders, or those with conditions that could affect cognitive function, will not be included. This trial is currently recruiting participants, and it's a valuable opportunity for those involved to contribute to important research that may improve understanding and treatment of FTLD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ability to undergo MRI scanning
• • For probable FTLD-tau: a clinical diagnosis of PSP, CBS or nfvPPA, or any clinical FTLD spectrum diagnosis with a proven MAPT mutation
• • For probable FTLD-TDP: a clinical diagnosis of svPPA or any clinical FTLD spectrum diagnosis with a proven GRN mutation or C9orf72 repeat expansion
• • For presymptomatic mutation carriers: a MAPT mutation, GRN mutation or a C9orf72 mutation without clinical sign of a FTLD spectrum phenotype (CDR 0) For control subjects: no known neurological or psychiatric disorder
• • For controls: no known neurological or psychiatric disorder
• Exclusion Criteria:
• • Other neurological or psychiatric disorder that may affect cognitive functions, such as a brain tumour, multiple sclerosis or drug or alcohol abuse or use of psycho-active medications
• • CSF profile (β-amyloid, p-tau, t-tau) suggestive of AD pathology
• • Clinical dementia Rating Scale (CDR) score \>1
• • Contra-indication to undergo MRI
• • Contra-indication to undergo lumbar puncture